USP14 inhibitor VLX1570 was the first DUB inhibitor to enter clinical trials for multiple myeloma therapy, but was deferred due to pulmonary toxicity (Wang et al., 2015; Rowinsky et al., 2020). Here, USP14 is linked to plasma cell myeloma.